Proskauer Rose

Proskauer Rose LLP is a prominent international law firm, headquartered in New York City, with over 800 lawyers across 12 offices in North and South America, Europe, and Asia. The firm is recognized as a BigLaw entity, ranking 41st on The American Lawyer's 2025 Am Law 200 with a gross revenue of over $1.39 billion for 2024. Vault Law 100 also places Proskauer Rose at #33 among U.S. law firms. Chambers USA and Global rankings further acknowledge its capabilities across numerous practice areas, including intellectual property.

Proskauer's patent litigation practice maintains a nationally recognized presence across diverse technology sectors. The firm is particularly active in life sciences, representing leading pharmaceutical, biologics, biotechnology, and medical device companies in complex patent disputes, as evidenced by its involvement in cases for clients like Haemonetics Corporation, Fresenius Kabi USA, LLC, and Regeneron Pharmaceuticals, Inc. Additionally, the firm handles matters in the technology sector, including software and networking, as seen in cases such as Uniloc USA, Inc. v. Microsoft Corporation, and has experience in patent standards. The firm demonstrates a balanced approach in its litigation, representing both plaintiffs and defendants, with its tracked cases showing 7 appearances for plaintiffs and 6 for defendants.

The firm has been involved in several high-stakes patent and related antitrust disputes. Proskauer served as defense counsel for Amgen Inc. in the Regeneron Pharmaceuticals, Inc. v. Amgen Inc. litigation, where a federal jury in Delaware district court found Amgen liable for antitrust and tort laws, awarding $406.8 million in damages to Regeneron in May 2025 for a drug bundling scheme, though the firm's specific involvement in this verdict is not detailed in public records. More directly, Proskauer secured a full defense verdict for Gilead Sciences, Inc. in a $3.6 billion HIV drug antitrust case in July 2023, which was recognized as one of the Daily Journal's "Top Verdicts for 2023."

Proskauer also maintains a significant practice before the Patent Trial and Appeal Board (PTAB), demonstrating strength in patent infringement litigation at both the PTAB and district courts. The firm actively engages in Inter Partes Review (IPR) and other contested patent office proceedings, advising clients on strategic considerations in light of evolving PTAB guidance and institution rates. Key partners leading Proskauer's patent litigation efforts include Joseph Drayton, Co-Head of the Patent Law practice, and Dr. Fangli Chen, Chair of the Life Sciences Patent Practice, both of whom are deeply involved in high-stakes intellectual property and patent challenges, including PTAB and IPR work. Erik B. Milch and Elizabeth Shrieves are also prominent attorneys involved in the firm's patent litigation and strategy.